- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05503511
Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects
April 3, 2023 updated by: NeuroPro Therapeutics, Inc.
A Single-center, Randomized, Placebo Controlled, Double-blind, Ascending Single-dose and Repeated-dose Trial to Determine the Safety and Pharmacokinetic Profile of NPT 2042 Soft-Gelatin Capsules Administered Orally to Healthy Adult Subjects
Study NPT 2042 CL 101 is a first in human (FIH) study to evaluate the safety and pharmacokinetics (PK) of single and repeated ascending doses of NPT 2042 in healthy adult male and female subjects.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The long-term goal of this program is to develop NPT 2042 an adjunct antiseizure treatment for patients with medically intractable epilepsy.
Prior to evaluating efficacy in the intended patient population, safety and pharmacokinetics of NPT 2042 will be investigated.
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Daryl Hochman
- Phone Number: (919) 812-0485
- Email: daryl@npt.io
Study Locations
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68502
- Celerion
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Body mass index (BMI) of 18 to 32 kg/m2, inclusive
- A minimum body weight of 50 kg for males and 45 kg for females
- All females must have a negative serum pregnancy test at Screening and a negative serum pregnancy test upon admission to the clinical research center.
- Females must be of nonchild-bearing potential defined as permanently sterile (i.e., due to hysterectomy) or postmenopausal (defined as more than one year since last menstrual period).
- Male subjects with female partners of reproductive potential must agree to practice abstinence or to use a condom (male subjects) plus an additional barrier method (female partner) of contraception for the duration of the study and for at least 90 days after dosing; subjects must also agree to refrain from sperm donation for at least 90 days after their last dose of IP.
- Able to swallow capsules.
Exclusion Criteria:
- Presence of active or recurring clinically-significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal, or metabolic disease requiring medical treatment.
- Presence of an active malignancy or a malignancy of any type within the past five years, other than squamous cell or basal cell carcinoma of the skin.
- Personal or family history of long QT syndrome.
- History or evidence of adverse symptoms associated with phlebotomy or blood donation (e.g., prolonged bleeding after injury or shaving, frequent epistaxis or gingival bleeding, bruises easily).
- History of clinically significant vertigo, dizziness or orthostatic hypotension or any vasovagal syncope or recurrent presyncope in connection with orthostatic challenge.
Reported use of or inability to refrain from or anticipated use of during the study
- any prescription drug within 14 days prior to dosing;
- any nonprescription drug, nutritional supplement, or vitamin within 7 days prior to dosing; NOTE: acetaminophen is allowed at a dose of ≤2000 mg/day
- any known enzyme-inducer or enzyme-inhibitor including St. John's Wort within 28 days prior to dosing, or
- reported chronic exposure to enzyme inducers such as paint solvents or pesticides within 30 days of dosing.
- Supine blood pressure (BP) less than 80/50 mmHg or greater than 140/90 mmHg.
- Supine heart rate <40 bpm and >90 bpm.
- History of drug abuse or current use of drugs of abuse or excessive ethanol intake
- Current Smoking, vaping, hookah, chewing tobacco, or history of smoking/vaping/chewing any substance
- Average consumption of ≥3 caffeine-containing beverages or xanthine-containing foods per day.
- Positive urine drug, alcohol, or cotinine result at screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A; Cohort 1
QD dosing of 10mg (1 day)
|
Soft gelatin capsules
|
Experimental: Part A; Cohort 2
QD dosing of 50mg (1 day)
|
Soft gelatin capsules
|
Experimental: Part A; Cohort 3
QD dosing of 160mg (1 day)
|
Soft gelatin capsules
|
Experimental: Part B; Cohort 1
Every 12-hour dosing of 20mg (7 days)
|
Soft gelatin capsules
|
Experimental: Part B; Cohort 2
Every 12-hour dosing of 40mg (7 days)
|
Soft gelatin capsules
|
Experimental: Part B; Cohort 3
Every 12-hour dosing of 80mg (7 days)
|
Soft gelatin capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events
Time Frame: Up to 11 days
|
Absolute values and change from baseline after a single dose or after 7 days of repeated dosing.
|
Up to 11 days
|
Number of participants with abnormal lab test results
Time Frame: Up to 11 days
|
Absolute values and change from baseline after a single dose or after 7 days of repeated dosing in clinical chemistry, hematology, and urinalysis.
|
Up to 11 days
|
Number of participants with abnormal vital signs
Time Frame: Up to 11 days
|
Absolute values and change from baseline after a single dose or after 7 days of repeated dosing in vital signs (oral body temperature, respiratory rate, blood pressure, and heart rate).
|
Up to 11 days
|
Number of participants with abnormal ECG
Time Frame: Up to 7 days
|
Absolute values and change from baseline after a single dose or after 7 days of ECG intervals.
|
Up to 7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic Cmax
Time Frame: 0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose
|
Maximum (peak) observed concentration of NPT 2042.
|
0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose
|
Pharmacokinetic Tmax
Time Frame: 0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose
|
Time to maximum observed concentrations of NPT 2042.
|
0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose
|
Pharmacokinetic half-life (t1/2)
Time Frame: 0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose
|
Time to terminal elimination half-life concentrations of NPT 2042.
|
0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose
|
Pharmacokinetic AUClast
Time Frame: 0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose
|
Area under the concentration-time curve from zero to the last concentration quantifiable for NPT 2042.
|
0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose
|
Pharmacokinetic AUCinf
Time Frame: 0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose
|
Area under the plasma concentration-time curve from time zero extrapolated to infinity for NPT 2042.
|
0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose
|
Pharmacokinetic CL/F
Time Frame: 0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose
|
Apparent total plasma clearance after oral administration of NPT 2042.
|
0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose
|
Pharmacokinetic VzF
Time Frame: 0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose
|
Apparent volume of distribution during terminal elimination phase after oral administration of NPT 2042.
|
0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose
|
Dose proportionality
Time Frame: 0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose
|
Dose proportionality of NPT 2042 will be assessed using the power model.
|
0 (predose) and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 24, 30, and 36 hours postdose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 20, 2022
Primary Completion (Actual)
March 17, 2023
Study Completion (Actual)
March 30, 2023
Study Registration Dates
First Submitted
July 28, 2022
First Submitted That Met QC Criteria
August 12, 2022
First Posted (Actual)
August 16, 2022
Study Record Updates
Last Update Posted (Actual)
April 4, 2023
Last Update Submitted That Met QC Criteria
April 3, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Epilepsy
- Alzheimer Disease
- Drug Resistant Epilepsy
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Sodium Potassium Chloride Symporter Inhibitors
- Bumetanide
Other Study ID Numbers
- NPT 2042 CL-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on NPT 2042 (bumetanide analog) or Matching Placebo
-
Huabo Biopharm Co., Ltd.Completed
-
Vertex Pharmaceuticals IncorporatedCompleted
-
Alzheon Inc.Quotient ClinicalCompleted
-
BenevolentAI BioCompletedAtopic DermatitisUnited Kingdom
-
Omeicos Therapeutics GmbHCompleted
-
Berlin Cures GmbHActive, not recruitingLong CovidGermany, Austria, Finland, Spain, Switzerland
-
GlaxoSmithKlineCompletedPain, InflammatoryUnited Kingdom, Germany, Poland
-
Zogenix International Limited, Inc., a subsidiary...Active, not recruitingLennox Gastaut SyndromeUnited States, Australia, Belgium, Canada, Denmark, France, Germany, Italy, Japan, Mexico, Netherlands, Poland, Spain, Sweden
-
GlaxoSmithKlineCompletedAnaemiaKorea, Republic of, Russian Federation, Spain, United States, Australia, United Kingdom, Brazil, Italy, Argentina, Poland, Romania, France, Canada